Home/Pipeline/MyoPAXon

MyoPAXon

Duchenne Muscular Dystrophy

Phase 1Active

Key Facts

Indication

Duchenne Muscular Dystrophy

Phase

Phase 1

Status

Active

Company

Myogenica

About Myogenica

Myogenica is a private, preclinical-stage biotech developing MyoPAXon, a universal iPSC-derived muscle stem cell therapy for muscular dystrophies. Founded by leading academic researchers and an experienced entrepreneur, the company leverages over a decade and $10M in grant-funded research from the University of Minnesota. With a Phase I trial in Duchenne muscular dystrophy slated for 2025, Myogenica aims to address a significant unmet need with a potentially durable, one-time treatment that regenerates functional muscle.

View full company profile

Therapeutic Areas

Muscular Dystrophy Duchenne Muscular Dystrophy Limb Girdle Muscular Dystrophy Facioscapulohumeral Muscular Dystrophy

Other Duchenne Muscular Dystrophy Drugs

Drug	Company	Phase	Status
DMD Gene Therapy	Kinea Bio	Pre-clinical	Active
NS-051/NCNP-04	NS Pharma	Phase 1/2	Active
UCT-MSC + Biomaterials	Vitti Labs	Phase 2	Active
Myosana Platform for DMD	Myosana Therapeutics	Pre-clinical	Active
PEPR-124 (RT-001)	Peptris Technologies Private	Phase 2-ready	Licensed to Revio Therapeutics
DMD Genetic Screening Panel	Nanodigmbio	Commercial	Active
KHR‑001	KAHR Medical	Preclinical	Active
PF-06939926	Pfizer	Phase 3	Active